Pembrolizumab for primary malignant melanoma of the central nervous system

Letter to the Editor

Notes

Acknowledgements

We thank Arnault de la Fouchardière, MD, PhD (Department of Biopathology, Centre Leon Berard, Lyon) for his work on the molecular analysis.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Research involving human and animals participants

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigm Cell Melanoma Res 24(5):879–897CrossRefGoogle Scholar
  2. 2.
    Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS (2016) The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 26(3):300–303CrossRefPubMedGoogle Scholar
  3. 3.
    Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havek JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyCentre hospitalier Régional Orléans La SourceOrléans Cedex 2France
  2. 2.Department of PathologyCentre hospitalier Régional Orléans La SourceOrléans Cedex 2France

Personalised recommendations